Go Pro
→ Iran War TRUTH: What Two Congressmen Led Me To (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
$0.01
$0.00
▼
$0.02
$1.02M-1.3212,302 shs1,289 shs
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$8.91
-74.1%		$12.36
$2.35
▼
$1,280.95
$11.88M-0.071.47 million shs11.55 million shs
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shs20,390 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.05
$276K0.11254,434 shs178,456 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00%-2.53%+10.00%-11.49%-46.90%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-74.14%+155.05%-34.87%-78.24%-99.16%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%+25.00%-37.50%-50.00%-90.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
$0.01
$0.00
▼
$0.02
$1.02M-1.3212,302 shs1,289 shs
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$8.91
-74.1%		$12.36
$2.35
▼
$1,280.95
$11.88M-0.071.47 million shs11.55 million shs
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shs20,390 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.05
$276K0.11254,434 shs178,456 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00%-2.53%+10.00%-11.49%-46.90%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-74.14%+155.05%-34.87%-78.24%-99.16%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%+25.00%-37.50%-50.00%-90.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
1.00
SellN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00
N/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SRNE, NMTR, EVFM, and JAGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.09N/AN/A($2.64) per share0.00
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$11.51M0.26N/AN/A($1,590.93) per share-0.01
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$0.19 per shareN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.00N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.13N/AN/AN/A-46.42%-91.97%-61.93%N/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$53.43M-$248.88N/AN/AN/A-187.88%N/A-131.45%11/12/2026 (Estimated)
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84M-$0.17N/AN/AN/AN/AN/AN/A11/6/2026 (Estimated)

Latest SRNE, NMTR, EVFM, and JAGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026Q2 2026
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$782.25-$15.70+$766.55-$235.50$4.24 million$1.23 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
N/AN/AN/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.35
0.69
0.40
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/A
0.59
0.59
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
12.04%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
22.34%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.01%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.18%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2.40%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120132.53 million113.12 millionNot Optionable
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
47340,000344,000No Data
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2014.34 million13.99 millionNo Data
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
949551.28 million536.95 millionNo Data

Recent News About These Companies

Sorrento Therapeutics stock reflects micro-cap status with minimal trading
September 19, 2026  |  ad-hoc-news.deA
Sorrento Voyage Announces Expanded Luxury Boat Tours and Proposal Experiences Along the Amalfi Coast
January 5, 2026  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE) - Investing.com
July 3, 2025  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion
SRNE Sorrento Therapeutics, Inc. - Seeking Alpha
June 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/SRNE
Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | Benzinga
April 19, 2025  |  benzinga.comhttps://www.benzinga.com/quote/SRNE
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
March 28, 2025  |  news.bloomberglaw.comN
Scilex says bankruptcy court extends lockup period on shares of Scilex dividend
January 31, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scilex-says-bankruptcy-court-extends-lockup-period-on-shares-of-scilex-dividend-1034296170
DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills
October 24, 2024  |  newsfilecorp.comN
Sorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO says
August 20, 2024  |  msn.comhttps://www.msn.com/en-us/health/medical/sorrento-enrols-60-of-80-patient-phase-ii-target-for-abivertinib-in-covid-19-futility-analysis-potentially-in-a-month-ceo-says/ar-AA1p7arP
Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter
May 29, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE)
May 25, 2024  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion/3
Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person
May 8, 2024  |  newsfilecorp.comN
DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing
May 1, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc SRNE
April 26, 2024  |  morningstar.comM
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Therapeutics
February 7, 2024  |  pharmaphorum.comP
5 Sanders Cove, Sorrento WA 6020
January 18, 2024  |  domain.com.auD
Sorrento Therapeutics, Inc. (0L85.L)
January 9, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/0L85.L/history/
Sorrento WA 6020
December 29, 2023  |  domain.com.auD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.0077 0.00 (0.00%)
As of 09/23/2026 02:27 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Jaguar Animal Health stock logo

Jaguar Animal Health NASDAQ:JAGX

$8.91 -25.55 (-74.14%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$8.12 -0.79 (-8.87%)
As of 09:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

9 Meters Biopharma stock logo

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0005 0.00 (0.00%)
As of 09/23/2026 03:46 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas